{'fraction_non_alphanumeric': 0.06221408966148216, 'fraction_numerical': 0.05489478499542543, 'mean_word_length': 4.819148936170213, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Enhanced sensitivity of ovarian cell line to cisplatin induced by mifepristone and its mechanism].

OBJECTIVE
To observe the effect of mifepristone in enhancing chemosensitivity of drug-resistant ovarian cancer cell line to cisplatin and investigate its mechanism.


METHODS
Human ovarian cancer cell lines COC1 (DDP-sensitive) and COC1/DDP (DDP-resistant) were incubated with or without mifepristone. The proliferation rate of the cells was determined by methyl thiazolyl tetrazolium (MTT) assay and positive expression of apoptosis-associated proteins Bcl-2 and Bax were observed by means of flow cytometry.


RESULTS
It was observed that mifepristone at the dose of 1.25 micromol/L reversed the resistance of COC1/DDP cells to cisplatin, and Bcl-2 protein expression was deceased from (23.8067+/-0.4382)% to (19.3967+/-0.6866)% (P=0.000) while Bax protein expression increased from (12.75+/-0.2524)% to (25.5967+/-0.8834)% (P=0.000).


CONCLUSION
Mifepristone may act to enhance the sensitivity of COC1/DDP cells to cisplatin, possibly through regulating Bcl-2 and Bax protein expressions.